Syndetics cover image
Image from Syndetics

Gilead Sciences and Sovaldi : the cost of a cure (B) / Benjamin Budish, Chase Lane, Richard Zaleski, James S. O'Rourke.

By: Contributor(s): Material type: TextSeries: Publisher: London : SAGE Publications Ltd, 2017Description: 1 online resourceContent type:
  • text
Media type:
  • computer
Carrier type:
  • online resource
ISBN:
  • 9781526403124 (ebook) :
Subject(s): DDC classification:
  • 174.4
Online resources: Gilead Sciences hepatitis C drug, Sovaldi, proved more effective than the competition and was priced in line with market conditions. However, extremely high cost and large patient population captured the attention of the media, the public, NGOs, and even the government. The controversy deepened when the company revealed the cost in developing countries would be roughly 1% of the cost in the U.S.
No physical items for this record

Originally published in Budish, B., Lane, C., Zaleski, R., & ORourke, J. S. (2014). Gilead Sciences and Sovaldi: The cost of a cure (B). 14-10 (B). Notre Dame, IN: The Eugene D. Fanning Center for Business Communication, Mendoza College of Business, University of Notre Dame.

Gilead Sciences hepatitis C drug, Sovaldi, proved more effective than the competition and was priced in line with market conditions. However, extremely high cost and large patient population captured the attention of the media, the public, NGOs, and even the government. The controversy deepened when the company revealed the cost in developing countries would be roughly 1% of the cost in the U.S.

Description based on XML content.

Licensed e-book